Emergent BioSolutions | EBS - Pre Tax Profit


Emergent BioSolutions reported $-130.8M in Pre-Tax Profit for its fiscal quarter ending in March of 2023.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Akebia Therapeutics USD -11.24M 12.39M Dec/2025
ALKERMES USD 100.74M 4.1M Sep/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Amarin USD -852K 7.26M Dec/2025
ANI Pharmaceuticals USD 49.52M 39M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Exelixis USD 252.69M 275K Dec/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
Ironwood Pharmaceuticals USD 68.02M 30.2M Sep/2025
Lexicon Pharmaceuticals USD -12.77M 16.02M Sep/2025
Lonza CHF 624M 197M Dec/2024
Merck USD 6.74B 22M Sep/2025
Moderna USD -187M 631M Sep/2025
Myriad Genetics USD 4.6M 3.4M Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Pacira USD 9.52M 11.45M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
United Therapeutics USD 444M 6M Dec/2025
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024
Xoma USD 15.98M 24.58M Jun/2024